Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression

Patricia S. Morel
Institut de Recherches Servier
April 1, 2022
PLoS One
https://pubmed.ncbi.nlm.nih.gov/35148334

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/35148334

Research summary

This study investigated the role of PCPE-1 in liver fibrosis and nonalcoholic steatohepatitis (NASH) progression. Using Pcolce Knockout (Pcolce^-/-) mice subjected to a choline-deficient, amino acid-defined high-fat diet (CDA HFD) for 8 weeks, researchers observed that PCPE-1 deficiency significantly reduced liver fibrosis, evidenced by decreased collagen deposition and cross-linking. However, PCPE-1 deficiency did not affect hepatic steatosis, inflammation, or liver dysfunction, indicating that while PCPE-1 contributes to fibrosis development, it does not influence the progression of NASH.

Key outcome of the study

PCPE-1 deficiency leads to reduced liver fibrosis without impacting steatosis or inflammation, suggesting its specific role in collagen maturation and fibrosis development in NASH.

Model

Global Pcolce Knockout (Pcolce^-/-) mouse model, generated by constitutive deletion of the Pcolce gene to study its role in liver fibrosis and NASH progression.

TARGET:
Pcolce
Procollagen C-Proteinase Enhancer-1

Keywords

Liver fibrosis, NASH, Collagen maturation, PCPE-1, Extracellular matrix remodeling

Technical specifications

Constitutive Knockout model, Pcolce gene deletion, CDA HFD-induced NASH model

Related products

Catalogue product

KO repository

>2000 conditional Knockout mouse models for target discovery and  confirmation, in vivo compound specificity, MOA, and clinical studies

Customized product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe